Wave Life Sciences Announces Approval Of First Clinical Trial Application For RestorAATion-2 Trial Of WVE-006 In Individuals With Alpha-1 Antitrypsin Deficiency
Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the approval of its first clinical trial